Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.

ABSTRACT: Two licensed vaccines block Plasmodium falciparum malaria sporozoites through anticircumsporozoite protein antibodies. In animal models, intradermal (ID) sporozoites are more readily blocked than intravenous sporozoites. We hypothesized that this complicates human studies, where infectious mosquito bites deliver a mixture of ID and venous sporozoites. Here, to test whether vaccine efficacy varies by route of inoculation, we undertook a phase 2b open, randomized controlled trial, recruiting healthy volunteers in Kenya for randomization to the circumsporozoite protein-based R21/Matrix-M vaccine (n = 38), thrombospondin-related adhesive protein fused to a multi-epitope string (ME-TRAP)-based vaccines (n = 24) or to control (n = 18). We enrolled 37 of these volunteers to controlled human malar

SUBMITTER: Kapulu MC 

PROVIDER: S-EPMC12823417 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature